Cortexyme, Inc. (CRTX)
| Market Cap | 1.09B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -82.76M |
| Shares Out | 29.59M |
| EPS (ttm) | -2.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $36.77 |
| Previous Close | $34.33 |
| Change ($) | 2.44 |
| Change (%) | 7.11% |
| Day's Open | 34.50 |
| Day's Range | 33.92 - 37.33 |
| Day's Volume | 139,156 |
| 52-Week Range | 26.66 - 58.99 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it belie...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a gr...
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are ...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to co...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, today announced Chris Low...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, announced that it has par...
Following the review of hepatic adverse events, the FDA has instituted a partial clinical hold impacting the open-label extension (OLE) phase of Phase 2/3 GAIN trial of Cortexyme Inc (NASDAQ: CRTX) eval...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, received a letter from th...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease on schedule to be announced in Q4 2021 and a pipeline of therapeu...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...
CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash.
Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...
Investors need to pay close attention to Cortexyme (CRTX) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer's and other degenerative diseases...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) today announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc.
Cortexyme: A New Approach To Defeat Alzheimer's Disease
A promising new approach could potentially yield a new drug providing hope for millions of Alzheimer's patients worldwide.
Cortexyme (NASDAQ: CRTX) is a clinical stage bio-pharmaceutical company working on Alzheimer’s and other degenerative diseases. The company currently has one molecule in its pipeline, called COR388, tha...
Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who ...
2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.
About CRTX
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Industry Biotechnology | IPO Date May 9, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol CRTX |
Analyst Forecasts
According to 8 analysts, the average rating for Cortexyme stock is "Buy." The 12-month stock price forecast is 71.29, which is an increase of 93.88% from the latest price.